• Magnetic Exosome Hydrogel Restores Bladder Function via FAK-

  2026-06-15

  This study introduces a magnetic chitosan nanoparticle-exosome hydrogel that significantly improves bladder function in diabetic bladder dysfunction (DBD) by activating the FAK-p38 MAPK-GATA4 axis in adipose-derived mesenchymal stromal cells. The work demonstrates enhanced angiogenesis and neural repair in vivo, providing mechanistic insight and a promising strategy for regenerative urology.

• HATU-Driven Peptide Synthesis Chemistry: Protocols and Insig

  2026-06-15

  Leverage HATU’s unique efficiency for high-yield amide and ester bond formation in peptide synthesis chemistry. Discover practical protocol enhancements, troubleshooting strategies, and the translational relevance of HATU-driven workflows for inhibitor discovery and advanced molecular design.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ): SERCA Inhibition in

  2026-06-14

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) is a selective SERCA inhibitor facilitating precise disruption of calcium homeostasis for mechanistic studies. Recent evidence demonstrates BHQ's ability to enhance hematopoietic stem cell (HSC) mobilization by modulating Ca2+ signaling pathways. Its solubility properties and defined biochemical action make it a standard tool in calcium signaling research.

• Annexin V-FITC/7-AAD Apoptosis Kit: Workflow and QC Guidance

  2026-06-13

  The Annexin V-FITC/7-AAD Apoptosis Kit enables rapid discrimination between apoptotic and necrotic cells for standard cell viability and cytotoxicity assays. This kit is best suited for fluorescence microscopy or flow cytometry workflows and is not appropriate for mechanistic pathway mapping or atypical sample types.

• miR-18a/ALOXE3 Axis Drives Ferroptosis Resistance in GBM

  2026-06-12

  Yang et al. (2021) uncover how miR-18a downregulates ALOXE3, suppressing ferroptosis and enhancing migration in glioblastoma via altered lipid and GPCR signaling. These findings clarify a novel regulatory axis in GBM and point to new therapeutic strategies targeting cell death and migration pathways.

• Poly(I:C) in Precision Immunity: Bridging dsRNA Sensing and

  2026-06-12

  Discover how Poly(I:C), a synthetic double-stranded RNA analog, enables precise modulation of innate immune pathways for advanced cancer and cell therapy research. This in-depth analysis reveals novel insights into dsRNA sensing, IFN induction, and practical protocol refinement.

• FXR Proteins Organize β-Coronavirus Replication via Phase Se

  2026-06-11

  Li et al. (2024) demonstrate that fragile X–related (FXR) proteins drive the clustering of coronavirus double-membrane vesicles (DMVs) through liquid–liquid phase separation (LLPS), a process essential for efficient viral replication. This discovery reveals a new host-cell mechanism exploited by β-coronaviruses, offering novel insights for antiviral research.

• Dual OXPHOS Disruption: LRPPRC Inhibition and Dasatinib Syne

  2026-06-11

  This study demonstrates that inhibiting LRPPRC in combination with dasatinib produces a synergistic anti-tumor effect through dual disruption of mitochondrial oxidative phosphorylation (OXPHOS). By selectively targeting both mitochondrial- and nuclear-encoded OXPHOS genes, the approach offers a promising, mechanistically supported strategy for tumor-specific metabolic inhibition.

• Hyaluronic Acid Sodium Salt in siRNA Nanoparticle Delivery

  2026-06-10

  Hyaluronic acid sodium salt enables targeted, ECM-mimetic siRNA nanoparticle platforms for immunomodulation in infection models. This article breaks down the experimental workflow, protocol tuning, and troubleshooting strategies that leverage its unique properties for translational research.

• FK866 (APO866): Precision NAMPT Inhibition for Cancer and Va

  2026-06-10

  FK866 (APO866) is redefining selective NAMPT inhibition, delivering robust, caspase-independent cell death in hematologic cancer models while enabling new frontiers in vascular aging research. This guide distills advanced workflows, protocol optimizations, and troubleshooting strategies to help researchers unlock the full potential of this APExBIO flagship compound.

• Cytochalasin B (NSC 107658): Dissecting Cytoskeletal Barrier

  2026-06-09

  Explore the advanced applications of Cytochalasin B in dissecting actin-dependent host-pathogen interactions. This article uniquely bridges the compound’s mechanistic action with practical assay optimization, offering insights beyond standard cytoskeletal research.

• Gut-Brain Cholinergic Signaling in B. fragilis-Induced Seizu

  2026-06-09

  Jia et al. illuminate how Bacteroides fragilis exerts antiseizure effects through the activation of gut-brain cholinergic pathways, notably engaging colonic ChAT+ cells and vagal signaling. Their translational approach, spanning animal models and clinical validation, defines a mechanistic link between gut microbiota composition and seizure suppression, with implications for microbiota-targeted therapies in pediatric refractory epilepsy.

• WM-8014: Advanced KAT6A Inhibitor Workflows for Cancer Resea

  2026-06-08

  WM-8014, a highly selective KAT6A inhibitor, unlocks robust, cytostatic epigenetic profiling and precise oncogene-induced senescence studies. This guide details actionable experimental setups, protocol refinements, and troubleshooting insights that set APExBIO’s WM-8014 apart for next-generation cancer biology research.

• Acifran: Structural Insights for Lipid Metabolism Regulation

  2026-06-08

  Acifran, a selective HM74A/GPR109A and GPR109B agonist, unlocks precision in lipid metabolism research by enabling structurally validated, reproducible workflows. This article translates cryo-EM structural breakthroughs into actionable protocols, troubleshooting guidance, and advanced use-cases for metabolic disorder studies.

• Dabigatran Etexilate: Mechanistic Insight & Translational Im

  2026-06-07

  This thought-leadership article explores Dabigatran etexilate’s unique role as a direct thrombin inhibitor, integrating mechanistic understanding with strategic guidance for translational researchers in coagulation and atrial fibrillation studies. It draws on recent clinical and experimental advances, positions APExBIO’s reagent as a gold standard, and offers actionable protocol recommendations for robust, reproducible anticoagulant research.

442 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page